ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects

There is an increasing interest for anaplastic lymphoma kinase (ALK) inhibitors in pediatric oncology for specific entities such as ALK-driven inflammatory myofibroblastic tumor (IMT). IMTtreatment can be challenging due to localization of the tumor and in rare cases of metastasis.When standard surgical treatment is not feasible, ALK inhibitors may play an important role,as recently reported for the first-generation ALK inhibitors (crizotinib). However, data on thesecond-generation ALK inhibitors are limited. We report two emblematic cases of IMT in pediatric patients, treated with the second-generation ALK inhibitor ceritinib in the context of a clinical trial(NCT01742286). READ ARTICLE

Pediatric Blood & Cancer DOI: 10.1002/pbc.27645

Authors: Erica Brivio and C. Michel Zwaan

Case StudyKirk SmithJanuary 18, 2019ALK inhibitors, ceritinib, inflammatory myofibroblastic tumor (IMT), pediatric oncology